Gh Research PLC GHRS

GHRS Quotes by TradingView
Institutional shares held 28.3 Million
10.3K calls
3.7K puts
Total value of holdings $255M
$92K calls
$33K puts
Market Cap $468M
52,020,800 Shares Out.
Institutional ownership 54.43%
# of Institutions 34

Quarterly Institutional Activity in GHRS

Shares Bought
Shares Sold
View Transactions

Top Institutions Holding GHRS

View all
View all

Latest Institutional Activity in GHRS

Top Purchases

Q1 2025
Palumbo Wealth Management LLC Shares Held: 12.9K ($116K)
12.9K Shares purchased
New Holding
Q4 2024
Lynx1 Capital Management LP Shares Held: 4.86M ($43.7M)
663K Shares purchased
15.8% Added
Q4 2024
Diadema Partners LP Shares Held: 102K ($914K)
102K Shares purchased
New Holding
Q4 2024
Peak6 LLC Shares Held: 59.2K ($533K)
59.2K Shares purchased
New Holding
Q4 2024
Woodline Partners LP Shares Held: 78.9K ($711K)
41.7K Shares purchased
112.01% Added
View All Buyers

Top Sells

Q4 2024
Verition Fund Management LLC Shares Held: 918K ($8.26M)
140K Shares sold
13.23% Reduced
Q4 2024
Bank Of America Corp Shares Held: 169 ($1.52K)
27.9K Shares sold
99.4% Reduced
Q4 2024
Barclays PLC Shares Held: 1.7K ($15.3K)
4.28K Shares sold
71.54% Reduced
Q4 2024
Renaissance Technologies LLC Shares Held: 30.3K ($273K)
100 Shares sold
0.33% Reduced
Q3 2024
Laurion Capital Management LP Shares Held: 48.4K ($435K)
16.6K Shares sold
25.53% Reduced
View All Sellers

About GHRS

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

GHRS Chart by TradingView
GHRS Fundamental Data by TradingView

Insider Transactions at GHRS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
0 Shares
From 0 Insiders
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on GHRS

Follow GH Research PLC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GHRS shares.

Notify only if
Any

Insider Trading

Get notified when an Gh Research PLC insider buys or sells GHRS shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to GH Research PLC

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on GHRS